Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.

Respiratory research·2024
Same author

Association between lung function and dyspnoea and its variation in the multinational Burden of Obstructive Lung Disease (BOLD) study.

Pulmonology·2024
Same author

Midregional proatrial naturetic peptide (MRproANP) and copeptin (COPAVP) as predictors of all-cause mortality in recently diagnosed mild to moderate COPD-results from COSYCONET.

Respiratory research·2024
Same author

Atrial fibrillation and survival on a medical intensive care unit.

International journal of cardiology·2023
Same author

[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIIN), the German Viological Society (DGV), the Competence Network CAPNETZ, the German College of General Practitioneers and Family Physicians (DEGAM), the German Society for Geriatric Medicine (DGG), the German Palliative Society (DGP), the Austrian Society of Pneumology Society (ÖGP), the Austrian Society for Infectious and Tropical Diseases (ÖGIT), the Swiss Respiratory Society (SGP) and the Swiss Society for Infectious Diseases Society (SSI)].

Pneumologie (Stuttgart, Germany)·2021
Same author

Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade.

Infection·2021
Same journal

Pneumologie (Stuttgart, Germany)·2026
Same journal

Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Correction: Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Erratum: Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Acute lung failure].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[The internet as a source of information for patients with sarcoidosis].

Pneumologie (Stuttgart, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Pneumonia -- historical development, current status, future prospects].

T Welte1

  • 1Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover. welte.tobias@mh-hannover.de

Pneumologie (Stuttgart, Germany)
|September 10, 2010
PubMed
Summary
This summary is machine-generated.

Pneumonia remains a significant global health threat, with rising antibiotic resistance and complex patient cases challenging modern treatments. Future strategies focus on understanding host-pathogen interactions and modulating innate immunity to combat pneumonia effectively.

More Related Videos

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Related Experiment Videos

Last Updated: Jun 9, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
07:43

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Area of Science:

  • Infectious Diseases
  • Immunology
  • Microbiology

Context:

  • Pneumonia presents persistent morbidity and mortality despite antibiotic advancements.
  • Increasingly, elderly and comorbid patients, alongside rising antibiotic resistance, create new therapeutic challenges.
  • Current research shifts from antibiotic development to host-pathogen interactions.

Purpose:

  • To review the evolving landscape of pneumonia treatment and research.
  • To highlight the limitations of traditional antibiotic-centric approaches.
  • To emphasize the growing importance of host-pathogen interactions and innate immunity modulation.

Summary:

  • Despite modern therapies, pneumonia's impact remains high due to demographic shifts and antimicrobial resistance.
  • Diagnostic improvements and risk stratification have standardized treatment protocols.
  • Vaccination strategies, such as for Streptococcus pneumoniae, have lessened disease burden.
  • Research is pivoting towards host-pathogen interactions and innate immune modulation as key to overcoming future challenges.

Impact:

  • This shift in research focus is crucial for developing novel therapeutic strategies against pneumonia.
  • Understanding innate immunity offers new avenues for managing complex and resistant pneumonia cases.
  • This approach may lead to more effective treatments for pneumonia in vulnerable populations.